Kyntra Bio (KYNB) Non Operating Interest Expenses (2014 - 2026)

For the trailing twelve months through Jun 30, 2026, Non Operating Interest Expenses at Kyntra Bio was $9.29 million, up 8.6% year-over-year; for FY2025, it came in at $8.76 million, up 6.2% from FY2024.

• Annual Non Operating Interest Expenses has increased for four consecutive years, with a five-year compound annual growth rate of 29.5% (FY2020 to FY2025).
• In prior years, Kyntra Bio's Non Operating Interest Expenses was $8.25 million in FY2024 (+1.9%), $8.1 million in FY2023 (+462.2%), $1.44 million in FY2022 (+34.0%) and $1.08 million in FY2021 (-55.2%).
• Quarterly Non Operating Interest Expenses has run from a low of -$2.37 million in Q4 2023 to a high of $5.02 million in Q3 2023 over five years.
• On a year-over-year basis, Non Operating Interest Expenses has increased in each of the last five quarters, with an average decline of 5.5% over the last seven quarters.
• The strongest year-over-year quarter for Non Operating Interest Expenses in the past five years was Q4 2022, with growth of 917.3%; the weakest was Q3 2021, with a decline of 81.2%.
• According to Business Quant data, Non Operating Interest Expenses for the three prior quarters was $2.43 million (Q1 2026), $2.41 million (Q4 2025) and $2.08 million (Q3 2025).